To clarify whether the therapeutic effects of JT003 relied on activating AdipoR1 and AdipoR2, RNA interference experiments were performed in NASH and fibrosis cell models. The gene discussed is ADIPOR2; the disease is metabolic dysfunction-associated steatohepatitis.